×
NAYA Biosciences Total Assets 2010-2024 | NAYA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
NAYA Biosciences total assets from 2010 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
View More
NAYA Biosciences Total Assets 2010-2024 | NAYA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
NAYA Biosciences total assets from 2010 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$169.8B
Vertex Pharmaceuticals (VRTX)
$121.4B
Gilead Sciences (GILD)
$109.7B
Bristol Myers Squibb (BMY)
$106.4B
Regeneron Pharmaceuticals (REGN)
$102.2B
CSL (CSLLY)
$92.8B
GSK (GSK)
$79.1B
Alnylam Pharmaceuticals (ALNY)
$36.5B
Argenex SE (ARGX)
$33.1B
BioNTech SE (BNTX)
$27.1B
Biogen (BIIB)
$26.7B
Illumina (ILMN)
$23.3B
Moderna (MRNA)
$21.2B
BeiGene (BGNE)
$21.1B
Genmab (GMAB)
$15.3B
Incyte (INCY)
$14.2B
BioMarin Pharmaceutical (BMRN)
$13.3B
Exact Sciences (EXAS)
$12.9B
Sarepta Therapeutics (SRPT)
$12.4B
Insmed (INSM)
$12.2B
Vaxcyte (PCVX)
$11.8B
Bio-Techne Corp (TECH)
$11.2B
QIAGEN (QGEN)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.3B
Roivant Sciences (ROIV)
$8.6B
Revolution Medicines (RVMD)
$8.4B
Legend Biotech (LEGN)
$8.3B
Exelixis (EXEL)
$8.2B
Viking Therapeutics (VKTX)
$8.2B
Intra-Cellular Therapies (ITCI)
$8.1B